Health Highlights: Oct. 16, 2014

October 16, 2014 4:31 PM

1 0

Two newly-approved drugs can slow the progression of a deadly lung disease, but there are concerns about the drugs' high prices.

Roche's Esbriet and Boehringer Ingelheim's Ofev were approved Wednesday by the U.S. Food and Drug Administration for treatment of people with idiopathic pulmonary fibrosis, The New York Times reported.

Read more

To category page